Registration Reminder: FDA Center for Veterinary Medicine Public Webinar about Genome Editing in Animals on Dec. 3
November 13, 2018
On December 3, 2018, the U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM), with participation from the FDA’s Center for Biologics Evaluation and Research (CBER), will hold a public webinar about genome editing in animals.
Genome editing is an innovative and rapidly evolving technology that offers many promising benefits to both human and animal health, animal well-being, and food production. This webinar is an initial step in FDA’s public communication strategy to help innovators understand FDA regulation and show support for safe and responsible innovation that benefits public health.
The webinar will focus primarily on the current scientific evidence, promising uses of this technology in animals, and the potential risks. It will also provide information about CVM’s flexible, risk-based approach to the regulation of intentional genomic alterations to animals and address common misconceptions associated with the regulation of these products. A portion of the webinar will be dedicated to answering stakeholder-submitted questions.
Genome editing in plants for human and/or animal food will not be covered.
The webinar is open to the public, but advance registration is required to participate in the live-cast webinar. To register, please visit CVM Public Webinar Genome Editing in Animals – Dec. 3, 2018, 1:00 – 3:00 pm ET.
Participants are encouraged to submit questions prior to the webinar during the registration process. Questions may also be submitted during the webinar.
A recording of the webinar will be available on the FDA website within 30 days of the event date.
- Registration: CVM Public Webinar about Genome Editing in Animals
- FDA’s Regulation of Plant and Animal Biotechnology Products
- FDA Plant and Animal Biotechnology Innovation Action Plan
- CVM Update: FDA Announces Plant and Animal Biotechnology Innovation Action Plan
- Statement from FDA Commissioner Scott Gottlieb, M.D., and Deputy Commissioner Anna Abram on the FDA’s new plan to advance plant, animal biotechnology innovation
For questions, Contact CVM.